Introgen gets second notice from Nasdaq, says it will fight removal from exchange Oct 7, 2008
the Austin drug company working to bring a head and neck cancer treatment to the market, has received its second delisting notice in two months from the Nasdaq stock exchange ... In early September, Introgen was dealt a significant blow when the U.S. Food and Drug Administration declined to accept the company s application to market its head and neck cancer drug Advexin. (Austin Business Journal, TX)
Eli Lilly bids $6.5 billion for ImClone Oct 7, 2008
" Lilly said it would incur a one-time charge to its earnings, but it is premature to say what that charge would be. The company expects the transaction to be accretive to earnings on a cash basis in 2012 and on a net basis in 2013. Cancer is one of the three main areas of research focus at Lilly, along with diabetes and neuroscience. But its main cancer drug, Gemzar, loses patent protection in 2012. Erbitux, which is approved to treat colon cancer and head and neck cancer, is ImClone's only... (Yahoo News -- Pharmaceutical Industry News)
Bring On The Pak Choi: Consumers Interested In Trying More Asian Vegetables Oct 6, 2008
16, 2007) A new study among AARP members shows that just one additional serving of fruit and vegetables per day may lower your risk of head and neck cancer, but the data suggest that you may not want to stop. (May 18, 2007) It turns out Mom was right -- you should eat your broccoli. (Science Daily)
Eli Lilly to buy ImClone for $6.5-billion Oct 6, 2008
Erbitux, which is approved to treat colon cancer and head and neck cancer, is ImClone's only marketed product, and generated $1. 3-billion in sales last year. (Globe and Mail -- Business)
News from Cancer: Disparities in head and neck cancer patients Oct 6, 2008
A new analysis finds considerable disparities in survival related to race and socio-economic status among patients with head and neck cancer ... To investigate factors that impact survival from head and neck cancer, Dr. Leonidas Koniaris and colleagues at the University of Miami School of Medicine reviewed all head and neck cancer cases in Florida between 1998 and 2002 ... By mining information from the Florida Cancer Data System and the Florida Agency for Health Care Administration dataset,... (EurekAlert!)
Anemia Drugs Linked To Stroke Study Deaths: FDA Oct 3, 2008
The committee also voted to recommend against the drugs' use in patients with breast or head and neck cancer. The new German study looked at the use of epoetin alfa as an aid to stroke recovery. (MEDLINEplus)
Gliknik locks up licenses to develop cancer drugs Sep 21, 2008
The biotech firm, creating drugs for autoimmune diseases and cancer, reached an agreement with the , Baltimore and the for the drugs, which are now in clinical trials for head and neck cancer. We are encouraged by the novelty and clinical trial results to date of these drug candidates and pleased to become a clinical stage development company early in the progress of our company s growth, said Gliknik CEO Dr. David Block in a statement. (Baltimore Business Journal, MD)
The fight of his life Sep 20, 2008
Until his illness, he was director of the Sydney Cancer Centre, director of the Sydney Head and Neck Cancer Institute, and professor of surgery at Sydney University since 2004. He was awarded an AM in 2005. (Sydney Morning Herald)
Patient-Reported Health Scores May Predict Head, Neck Cancer Outcomes Sep 19, 2008
WEDNESDAY, Sept. 17 (HealthDay News) -- Self-reported physical health changes in the year after head and neck cancer patients are diagnosed may help predict their five-year survival, says a U.S. study ... 7) diagnosed with head and neck cancer between 1995 and 2005 ... The researchers concluded that it may prove useful to include a measure of general health and well-being to the care of patients with head and neck cancer, especially during the first year. (MEDLINEplus)
Now Back To Icahn Sep 12, 2008
The results of a study released Wednesday by ImClone showed that Erbitux, mainly used to treat colon cancer, would also be effective in the treatment of head and neck cancer. The late-stage human trial showed a median survival increase of 2. (Forbes -- Markets)
Erbitux Extends Life for Head and Neck Cancer Patients Sep 12, 2008
The drug has been used successfully in metastatic colon cancer and now appears to also benefit patients with head and neck cancers. "This is the first treatment in 30 years to prolong survival in first-line recurrent and/or metastatic head and neck cancer," said lead researcher Dr. Jan B. Vermorken, of the Department of Oncology at Antwerp University Hospital, in Belgium ... For this phase III trial, Vermorken's group randomly assigned 442 patients with recurrent metastatic head and neck cancers... (MEDLINEplus)
ImClone mulls $6.1b buyout offer Sep 11, 2008
Yesterday, ImClone formally rejected that offer from Bristol-Myers, its partner in selling Erbitux, a treatment for colon and head and neck cancer. "In our view, this will force [Bristol-Myers's] hand to offer $70 with no due diligence conditions immediately," analyst Barbara Ryan wrote in a note to clients. (Boston Globe)
ImClone's Erbitux Extends Head, Neck Cancer Survival in Study Sep 11, 2008
s Erbitux prolongs survival for patients with recurring head and neck cancer more than chemotherapy alone, a ``notable'' potential treatment improvement, according to a report in the ... About 40,000 people in the U.S. are diagnosed with head and neck cancer every year, and 40 percent have spreading disease. (Bloomberg)
ImClone gets second takeover bid Sep 11, 2008
Erbitux, ImClone's main product, is approved to treat colon cancer and head and neck cancer. Any second bidder would have to deal closely with Bristol-Myers, which holds a 20 percent stake in ImClone. (International Herald Tribune -- Business)
Recent Advances in Head and Neck Cancer Sep 11, 2008
Volume 359:1143-1154. Robert I. Haddad, M.D., and Dong M. Shin, M.D.. (New England Journal of Medicine)
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer Sep 11, 2008
Volume 359:1116-1127. Jan B. Vermorken, M.D., Ph. (New England Journal of Medicine)
As head and neck cancer risks evolve, more treatment options emerge Sep 11, 2008
Advances in understanding head and neck cancer over the last decade have led to more treatment options and improved quality of life for patients, according to a review published this week in the New England Journal of Medicine ... At Winship, Shin is leading a head and neck cancer drug discovery program and conducting clinical trials aimed at preventing head and neck cancers from progressing or recurring ... He and his co-workers recently showed that a compound from green tea enhances the... (EurekAlert!)
Introgen sell-off continues Sep 5, 2008
On Tuesday Austin-based Introgen announced the FDA had declined to accept its application to market Advexin, the head and neck cancer drug the company has spent more than a decade developing. That news prompted Introgen s (Nasdaq: INGN) stock to drop more than 35 percent on Tuesday to 57 cents a share. (Austin Business Journal, TX)
FDA refuses Introgen application; stock in freefall Sep 3, 2008
Introgen (Nasdaq: INGN) says the FDA has notified the company that its application for its Advexin head and neck cancer treatment was not complete and would therefore not be filed at this time ... We believe in the potential of Advexin as a treatment option for head and neck cancer, an area of significant unmet need for today s cancer patient, says Introgen CEO David Nance ... We are encouraged by our clinical data and believe that the 40,000 Americans who are diagnosed with head and neck cancer... (Austin Business Journal, TX)
ImClone: BMS offer for company seen reaching USD 67-70 Aug 29, 2008
Alternatively, the person familiar said he believes that more mileage could be derived from Erbitux, which, in combination with radiation therapy, is indicated for the treatment of a certain type of locally or regionally advanced head and neck cancer. He said that going forward the drug in colorectal cancer has proven to double survival rates in third line and has proven results in non-small cell lung cancer, which he noted has a larger indication. (FT.com -- Markets)
Cancer slows UConn coach Calhoun but doesn't stop him Aug 26, 2008
" The most recent battle began as soon as Calhoun realized he was dealing with something worse than an upper respiratory infection brought on by the end of another season. After telling his doctors the growth had increased in size, a biopsy was performed April 24. Jeffrey Spiro, co-director of the Multidisciplinary Head and Neck Cancer Team at the UConn Health Center, operated without Calhoun's condition becoming public knowledge, but it was obvious radiation treatments would change that. Spiro... (USA Today -- Sports)
Cel-Sci lets Teva sell cancer drug Aug 20, 2008
The licensing agreement is initially restricted to the areas of head and neck cancer. Teva has the rights, subject to certain conditions, to extend the licensing agreement to include other cancers during the term of this agreement. (Washington Business Journal, DC)
Adherex Reports Second Quarter 2008 Financial Results Aug 13, 2008
- In May, we completed a license agreement with the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NCI-AVL) for the exclusive use of data from a completed Phase III trial using sodium thiosulfate (STS) to prevent platinum-induced hearing loss in adults with head and neck cancer ... We also have plans to initiate a further Phase III trial with STS in adult head and neck cancer patients in the U.S. later this year. (CCNMatthews Press Releases)
ImClone Calls Bristol Offer Too Low Aug 5, 2008
Erbitux is approved for colorectal and head and neck cancer in the United States, and Canada, while a recent approval for the drug in Japan and new lung cancer data are expected to drive sales. ImClone said it believed the pipeline business "may be extremely valuable and significantly increase stockholder value as a separate business.". (ABC News -- Wire)
Bristol offers to buy ImClone for $60 a share Aug 1, 2008
Bristol co-promotes Erbitux, which is approved for colorectal and head and neck cancer, in the United States, and Canada, while a recent approval for the drug in Japan and new lung cancer data are expected to drive sales. Germany's Merck KGaA () has rights to Erbitux in other countries. (Yahoo News -- Pharmaceutical Industry News)
Bristol-Myers offers $4.5 billion for ImClone Aug 1, 2008
New York-based Bristol-Myers already owns about 17 percent of ImClone and is a longtime U.S. partner on the colon and head and neck cancer drug Erbitux. In my view, and in the view of our board of directors, this transaction makes compelling business sense for both of our companies and is in the best interests of our respective shareholders and the cancer patients for whom our companies life saving medicines are so important, Bristol-Myers Chairman and Chief Executive James M. Cornelius... (MSNBC -- Business)
US stocks slide on GDP, jobless data Aug 1, 2008
Web search enhanced by. Friday August 1, 2008 MYT 12:17:42 PM. (The Star Online, Malaysia -- Business)
Wall Street slides on GDP, jobless data Aug 1, 2008
Bristol-Myers, which already owns about 17 percent of ImClone, is a U.S. partner for the colon and head and neck cancer drug Erbitux. ImClone surged $17. (San Diego Union-Tribune)
U.S. regulator to tighten use of Amgen anemia drugs Jul 31, 2008
But the new labels will not advise against use of the drugs for all patients with breast cancer or head and neck cancer, something that had been recommended by an advisory panel to the FDA in March. One impact of the label changes could be to make it less likely that Medicare will loosen reimbursement policies for the drugs. (International Herald Tribune -- Money Report)
Oncolytics Biotech Inc. Announces 2008 Second Quarter Results Jul 30, 2008
"Oncolytics experienced a strong second quarter with the reporting of durable clinical responses to REOLYSIN(R) combination therapy treatment in refractory head and neck cancer patients," said Dr. Brad Thompson, President and CEO of Oncolytics ... MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with the unaudited interim consolidated financial statements of Oncolytics Biotech Inc. as at and for the... (PR Newswire)
Dr. Pou's trial changes laws and her life Jul 30, 2008
Today, she is busy as a head and neck cancer specialist and surgeon. She is on the faculty of LSU Health Sciences Center in New Orleans and treats her patients and the needy of the state, commuting to clinics set up in Baton Rouge. (WWLTV.com, LA)
Teamwork Cuts Out Unnecessary Biopsies, Researchers Find Jul 26, 2008
ScienceDaily (July 25, 2008) Unnecessary biopsies could be a thing of the past for patients undergoing treatment for head and neck cancer ... Often used prior to and after cancer treatment, the highly sensitive PET-CT has improved the ability to detect and treat head and neck cancer ... Unnecessary biopsies are dangerous for head and neck cancer patients who have already undergone intensive radiation and chemotherapy. (Science Daily)
Head And Neck Cancer: Quick Way To Determine If Cancer Has Spread Jul 25, 2008
ScienceDaily (July 24, 2008) For patients with head and neck cancer, accurately determining how advanced the cancer is and detecting secondary cancers usually means undergoing numerous tests - until now. New Saint Louis University research has found that the PET-CT scanner can be used as a stand-alone tool to detect secondary cancers, which occur in 5 to 10 percent of head and neck cancer patients ... The study findings, which were presented on July 22, at the 7th International Conference on... (Science Daily)
US surgeons to honour RPA doctor Jul 20, 2008
The popular professor is in San Francisco, with his wife Gail, at the 7th International Conference on Head and Neck Cancer. A keynote lecture named in his honour will be delivered tomorrow. (Sydney Morning Herald -- Australia)
Gene Variations In Diverse Patient Populations Determine Who Responds Best To An Antidepressant Jul 17, 2008
(May 19, 2008) Taking the antidepressant citalopram before beginning treatment for head and neck cancer may help prevent depression during therapy, according to results of a pilot. (Mar. (Science Daily)
Adam Feuerstein Jul 15, 2008
But in his article Feuerstein says that "doesn't explain why survival for Advexin-treated patients overall was so low." He goes on to say: "Introgen says that 75 percent of head and neck cancer patients are 'Advexin favorable' so surely, that should translate into a survival benefit no matter how the patients are analyzed.". On June 30 Austin-based Introgen -- which has most of its staff and operations in Houston and only its executive team in Austin -- announced it had applied with the U.S.... (Austin Business Journal, TX)
Amgen to Pay J&J $200 Million to Settle Antitrust Suit Jul 13, 2008
A panel of experts recommended in March that the U.S. Food and Drug Administration change the drugs' labels to say that they should not be given to patients with potentially curable cancers who are undergoing treatment, or to patients with advanced breast cancer or head and neck cancer. A decision by the FDA is expected any day. (ABC News -- Wire)
Introgen cuts 29% of jobs as it moves to market cancer therapy Jul 8, 2008
Advexin p53 is designed to treat recurrent head and neck cancer. By harnessing the body's natural tumor-suppression mechanisms, the treatment fights cancer without some of the toxicities associated with conventional cancer treatments. (Austin Business Journal, TX)
Introgen stock rises as company seeks FDA approval of cancer drug Jul 1, 2008
Advexin p53 is designed to treat recurrent head and neck cancer ... "With the use of p53 biomarkers, Advexin will provide more effective and less toxic treatment for head and neck cancer patients who have limited treatment options.". (Austin Business Journal, TX)
GlaxoSmithKline, Exelixis to end 6-year collaboration Jun 28, 2008
The compound, now called GSK089, is in Phase II trials for papillary renal cell carcinoma, gastric cancer and head and neck cancer. GSK can pick an additional compound among six programs: XL184, which will start Phase III trials this summer for glioblastoma, medullary thyroid cancer and non-small cell lung cancer; XL820, in Phase II for gastrointestinal stromal tumor; XL281, in Phase I for patients with advanced solid tumors; XL228, in Phase I for chronic myelogenous leukemia, Philadelphia... (San Francisco Business Journal)
Caphosol favorably impacts both the rate and severity of oral mucositis in cancer patients Jun 28, 2008
The most common malignancies among the participants were breast cancer (31 percent), head and neck cancer (31 percent) and colorectal cancer (11 percent) ... The use of Caphosol also had a favorable impact on the severity of OM: Mild OM (Grade 0/1) was found in more than 90 percent of chemotherapy patients and 40 percent of head and neck cancer patients ... Severe OM (Grade 3/4) was found in only 1-2 percent of chemotherapy patients and 18 percent of head and neck cancer patients (with only one... (EurekAlert!)
Cancer center celebrates an anniversary Jun 25, 2008
"We have a whole generation of head and neck cancer patients who will never get surgery now because we have proved that combination therapy can be just as effective without the need for surgery," Foens said. "If those patients had to coordinate their treatments in Waterloo and Grundy Center or Mason City it would be very difficult for them to continue on with their daily activities. ... This kind of practice was revolutionary 20 years ago, but it is still meeting our patients' needs today.". (Waterloo-Cedar Falls Courier)
YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL Jun 20, 2008
It is approved in several countries for treatment of various types of head and neck cancer. This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. (PR Newswire)
An HIV-Positive Man with Cutaneous Merkel-Cell Carcinoma Jun 19, 2008
Dr. Gregory K. Robbins (Infectious Diseases): A 63-year-old man was referred to the clinic for head and neck cancer, a multidisciplinary unit of this hospital, for management of cutaneous Merkel-cell carcinoma. He had been well until 3 months earlier, when he noted a small, painless nodule on the superior, right-central aspect of his forehead. (New England Journal of Medicine)
Combining Radiation And Surgery Significantly Improves Survival For Head And Neck Cancer Patients Jun 15, 2008
14, 2008) Adding radiation therapy to surgery significantly improves overall survival in patients diagnosed with node-positive head and neck cancer when compared to treating with surgery alone, according to a study in the June issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology ... Radiation therapy is commonly used after surgery to treat some head and neck cancers, but very few studies have... (Science Daily)
Police chief battles cancer, speaks out against chew tobacco Jun 5, 2008
"I was still trying to recover from being cut head to toe when they sent me to chemo and radiation," said Hahn, 33, who was diagnosed with head and neck cancer in April 2007 ... Four days later Hahn was diagnosed with head and neck cancer and scheduled for emergency surgery at the Huntsman Cancer Institute at the University of Utah in Salt Lake City. (Casper Star-Tribune, WY)
Drugs show success in the treatment of several cancers Jun 3, 2008
Patients with locally advanced head and neck cancer may respond better to treatment when the drug cetuximab is added to standard chemotherapy, according to findings presented by University of Pittsburgh researchers yesterday in Chicago at the annual meeting of the American Society of Clinical Oncology. Out of 37 patients, 32 responded to initial therapy with that treatment regimen, and all patients had full or partial reduction of their tumors later after radiation treatment, said Dr. Ethan... (Pittsburgh Post Gazette)
Anemia Drugs May Speed Tumor Growth in Some Cancer Patients Jun 3, 2008
They also voted to recommend against the drugs' use in patients with breast or head and neck cancer ... The results of the current study were based on analyses of tumor samples from 101 patients diagnosed with head and neck cancer who had participated in a previous phase III trial of erythropoietin. (MEDLINEplus)
Acupuncture Eases Side Effects of Head, Neck Cancer Treatments Jun 3, 2008
SUNDAY, June 1 (HealthDay News) -- Two of the more common and unpleasant side effects of treatment for head and neck cancer patients may be relieved by the ancient Chinese practice of acupuncture ... Neck dissection, or removal of the lymph nodes and surrounding tissue, is common in treating head and neck cancers. (MEDLINEplus)
Study is seen as boost for ImClone Jun 2, 2008
It is also approved to treat head and neck cancer. But data presented here could change that. (Boston Globe)
UPDATE:Colon Cancer Study Backs Gene's Role In Erbitux Benefit Jun 2, 2008
It is already approved to treat head and neck cancer, as well as colorectal cancer that has failed previous therapy. The response rate in the Erbitux arm was 59% in wild-type patients, compared to 43% in chemotherapy alone. (CNNMoney.com)
Easing The Pain After Cancer Surgery Jun 2, 2008
Acupuncture eases pain in head and neck cancer surgery Posted: 02 June 2008 1510 hrs. Photos. (Channelnewsasia.com)
Cancer drug developed by Introgen founder meets with clinical success Jun 1, 2008
Advexin, a modified adenovirus that uses the tumor-suppressing gene p53, is being used for end-stage head and neck cancer. Introgen co-founder and M.D. Anderson Professor Jack Roth invented the drug. (Austin Business Journal, TX)
Acupuncture reduces pain and dysfunction in head and neck cancer patients after neck dissection Jun 1, 2008
New data from a randomized, controlled trial found that acupuncture provided significant reductions in pain, dysfunction, and dry mouth in head and neck cancer patients after neck dissection ... Neck dissection is a common procedure for treatment of head and neck cancer. (EurekAlert!)
Gene Therapy Increases Survival For End-stage Head And Neck Cancer May 30, 2008
Introgen Therapeutics, Inc., reported results of its phase III trial of Advexin(r), a modified adenovirus that expresses the tumor-suppressing gene p53, for end-stage head and neck cancer ... The trial showed that p53 expression in the patient's tumor before treatment is a reliable biomarker for how to treat head and neck cancer ... Introgen developed a commercial-grade version of the drug and advanced it through phase II and III clinical trials for head and neck cancer. (Science Daily)
Quality of life predicts cancer survival, U-M study finds May 30, 2008
Head and neck cancer patients who reported lower physical quality of life were more likely to die from their disease, according to a new study from the University of Michigan Comprehensive Cancer Center ... The researchers surveyed 495 people at four hospitals who had been diagnosed with head and neck cancer within the previous two years ... Based on their findings, the study authors recommend routine quality of life assessments of patients with head and neck cancer, before treatment and again... (EurekAlert!)
New Immunization Strategy Could Be Effective Against 10 To 15 Percent Of All Cancers May 28, 2008
20, 2007) Researchers have developed a vaccine strategy for head and neck cancer that targets multiple peptides to activate the immune system to attack tumors. Their findings on cancer vaccines will be. (Science Daily)
Fruit, Veggies May Lower Head and Neck Cancer Risk May 27, 2008
Smoking and heavy drinking are two major risk factors for head and neck cancers, but even when the researchers accounted for such lifestyle factors, fruits and vegetables remained linked to lower cancer risks ... Past studies have suggested that fruits and vegetables and the nutrients they contain -- including various antioxidant compounds -- might help protect against head and neck cancers ... For example, participants who ate the most vegetables -- typically between three and four servings a... (MEDLINEplus)
Antidepressant May Help Head/Neck Cancer Patients May 27, 2008
NEW YORK (Reuters Health) - The results of a pilot study suggest that antidepressant therapy with Celexa during treatment for head and neck cancer reduces the risk of depression and diminishes the impact of cancer treatment on quality of life. Depression has been reported in up to 40 percent of patients with head and neck cancer "typically within the first 3 months of diagnosis," Dr. William M. Lydiatt and colleagues write in the journal, Archives of Otolaryngology -- Head and Neck Surgery ...... (MEDLINEplus)
U of L researchers link HPV with head, neck cancers May 21, 2008
Cancer researchers at the 's James Graham Brown Cancer Center have found that the human papillomavirus (HPV) is present in about one-third of head and neck cancers studied. The research team, led by U of L resident Payal Desai, looked at tissue samples from 43 patients with head and neck cancer of unknown origin ... "These results indicate that current vaccines, which protect against the HPV 16 virus, could prevent a large number of head and neck cancer cases," the university said in the... (Louisville Business First, KY)
Young woman opts for double mastectomy, removal of ovaries to beat cancer threat May 18, 2008
It is unclear if the gene is linked to the head and neck cancer she had in 1988. Stoltz also plans to have a double mastectomy to reduce her risk of developing breast cancer a second time. (Montana Standard, MT)
CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients May 17, 2008
These data confirm that CAPHOSOL is a useful tool to help oncology nurses and other healthcare professionals in the management of OM and related symptoms, particularly in patients with head and neck cancer and those receiving chemotherapy ... The rate of severe oral mucositis (NCI Clinical OM Grade 3-4) reported by head and neck cancer patients using CAPHOSOL in this study was 11% (Grade 3) and 2% (Grade 4) ... Historically, the incidence of severe OM in head and neck cancer patients receiving... (EurekAlert!)
Imclones Erbitux BMS-099 trial not powered to show overall survival, FLEX remains pivotal registrational trial May 16, 2008
Erbitux is a monoclonal antibody currently approved to treat head and neck cancer and colon cancer. It is also being tested for use in non-small cell lung cancer (NSCLC), with key trial results expected at the upcoming American Society of Clinical Oncology conference in Chicago. (FT.com -- Markets)
HPV Linked To Better Survival In Tonsil, Tongue Cancer, Study Finds May 15, 2008
Cancers of the tonsils and the base of the tongue have increased in recent years, in what Carey calls an "epidemic" of HPV-induced head and neck cancer. This has occurred at the same time that declines in smoking rates have led to a decrease in the incidence of other types of head and neck cancers ... About 35,300 Americans will be diagnosed with head and neck cancer this year, according to the American Cancer Society. (Science Daily)
Does Brushing Teeth Fight Lung Cancer May 15, 2008
The rates went up 68 percent for head and neck cancer and 54 percent for lung cancer. The researchers also found that the more teeth someone lost, the greater the chance of cancer. (Click2Houston, TX)
